Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 21Lymphoma, Mantle-Cell 15Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Lymphoma, B-Cell 3Leukemia, B-Cell 3Waldenstrom Macroglobulinemia 2Lymphatic Diseases 2Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Glioblastoma 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1

Interventions

obinutuzumab 1empagliflozin 1acalabrutinib 1Rituximab 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Failure × acalabrutinib × 90 days × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡